Longitudinal Molecular Magnetic Resonance Imaging of Endothelial Activation after Severe Traumatic Brain Injury.

endothelial activation neuroimaging neuroinflammation traumatic brain injury

Journal

Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588

Informations de publication

Date de publication:
30 Jul 2019
Historique:
received: 20 06 2019
revised: 26 07 2019
accepted: 29 07 2019
entrez: 2 8 2019
pubmed: 2 8 2019
medline: 2 8 2019
Statut: epublish

Résumé

Traumatic brain injury (TBI) is a major cause of death and disability. Despite progress in neurosurgery and critical care, patients still lack a form of neuroprotective treatment that can counteract or attenuate injury progression. Inflammation after TBI is a key modulator of injury progression and neurodegeneration, but its spatiotemporal dissemination is only partially known. In vivo approaches to study post-traumatic inflammation longitudinally are pivotal for monitoring injury progression/recovery and the effectiveness of therapeutic approaches. Here, we provide a minimally invasive, highly sensitive in vivo molecular magnetic resonance imaging (MRI) characterization of endothelial activation associated to neuroinflammatory response after severe TBI in mice, using microparticles of iron oxide targeting P-selectin (MPIOs-α-P-selectin). Strong endothelial activation was detected from 24 h in perilesional regions, including the cortex and hippocampus, and peaked in intensity and diffusion at two days, then partially decreased but persisted up to seven days and was back to baseline 15 days after injury. There was a close correspondence between MPIOs-α-P-selectin signal voids and the P-selectin stained area, confirming maximal endothelial activation at two days. Molecular MRI markers of inflammation may thus represent a useful tool to evaluate in vivo endothelial activation in TBI and monitoring the responses to therapeutic agents targeting vascular activation and permeability.

Identifiants

pubmed: 31366109
pii: jcm8081134
doi: 10.3390/jcm8081134
pmc: PMC6722937
pii:
doi:

Types de publication

Journal Article

Langues

eng

Subventions

Organisme : Ministero della Salute (Italy) within the framework of ERA-NET NEURON.
ID : -

Références

Circulation. 2000 Oct 17;102(16):1931-6
pubmed: 11034941
NeuroRx. 2005 Apr;2(2):372-83
pubmed: 15897957
J Neurotrauma. 2007 Apr;24(4):657-73
pubmed: 17439349
Nat Med. 2007 Oct;13(10):1253-8
pubmed: 17891147
NeuroRehabilitation. 2007;22(5):341-53
pubmed: 18162698
Neuroimage. 2008 Aug 1;42(1):60-9
pubmed: 18502665
Neuroimage. 2009 Jul 1;46(3):786-802
pubmed: 19195496
J Neurotrauma. 2009 Sep;26(9):1509-19
pubmed: 19663686
J Neurotrauma. 2010 Jul;27(7):1343-53
pubmed: 20392140
Neuroimage. 2011 Feb 1;54(3):2033-44
pubmed: 20851191
J Leukoc Biol. 2011 Apr;89(4):539-56
pubmed: 21169520
Neurotherapeutics. 2011 Jan;8(1):39-53
pubmed: 21274684
J Pharmacol Pharmacother. 2010 Jul;1(2):94-9
pubmed: 21350617
Ann Neurol. 2011 Sep;70(3):374-83
pubmed: 21710619
FASEB J. 2011 Dec;25(12):4415-22
pubmed: 21908714
Neuroimage. 2012 Aug 15;62(2):774-81
pubmed: 22248573
Transl Stroke Res. 2011 Dec;2(4):492-516
pubmed: 22299022
Proc Natl Acad Sci U S A. 2012 Apr 24;109(17):6674-9
pubmed: 22451897
Cell Adh Migr. 2012 Sep-Oct;6(5):390-6
pubmed: 22902764
Nat Methods. 2012 Jul;9(7):671-5
pubmed: 22930834
J Neurosci. 2012 Dec 12;32(50):17948-60
pubmed: 23238711
J Cereb Blood Flow Metab. 2013 Jun;33(6):834-45
pubmed: 23443171
Stroke. 2013 Jul;44(7):1988-96
pubmed: 23743972
Neuroscience. 2014 Jul 11;272:199-206
pubmed: 24792709
J Neurosci. 2014 Dec 3;34(49):16180-93
pubmed: 25471560
Front Cell Neurosci. 2014 Nov 27;8:389
pubmed: 25505871
Curr Neurol Neurosci Rep. 2016 Apr;16(4):29
pubmed: 26883431
Brain. 2017 Jan;140(1):146-157
pubmed: 28031221
Proc Natl Acad Sci U S A. 2017 Jun 6;114(23):6116-6121
pubmed: 28533365
BMC Neurosci. 2017 Jun 26;18(1):51
pubmed: 28651647
Shock. 2018 Nov;50(5):551-556
pubmed: 29140832
Theranostics. 2018 Feb 2;8(5):1195-1212
pubmed: 29507614
Brain Behav Immun. 2018 Jul;71:9-17
pubmed: 29601944
J Neuroimmunol. 2019 Jul 15;332:112-125
pubmed: 31005712
Proc Natl Acad Sci U S A. 2019 May 28;116(22):11010-11019
pubmed: 31097598
Front Neurol. 2019 Jun 06;10:582
pubmed: 31275220

Auteurs

Gloria Vegliante (G)

Department of Neuroscience, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, 20156 Milano, Italy.

Daniele Tolomeo (D)

Department of Neuroscience, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, 20156 Milano, Italy.

Antoine Drieu (A)

INSERM, INSERM UMR-S U1237, Physiopathology and Imaging of Neurological Disorders, Normandie University, UNICAEN, Institut Blood and Brain @ Caen-Normandie, GIP Cyceron, 14000 Caen, France.

Marina Rubio (M)

INSERM, INSERM UMR-S U1237, Physiopathology and Imaging of Neurological Disorders, Normandie University, UNICAEN, Institut Blood and Brain @ Caen-Normandie, GIP Cyceron, 14000 Caen, France.

Edoardo Micotti (E)

Department of Neuroscience, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, 20156 Milano, Italy.

Federico Moro (F)

Department of Neuroscience, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, 20156 Milano, Italy.

Denis Vivien (D)

INSERM, INSERM UMR-S U1237, Physiopathology and Imaging of Neurological Disorders, Normandie University, UNICAEN, Institut Blood and Brain @ Caen-Normandie, GIP Cyceron, 14000 Caen, France.
Department of Clinical Research, Caen-Normandie University Hospital, 14000 Caen, France.

Gianluigi Forloni (G)

Department of Neuroscience, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, 20156 Milano, Italy.

Carine Ali (C)

INSERM, INSERM UMR-S U1237, Physiopathology and Imaging of Neurological Disorders, Normandie University, UNICAEN, Institut Blood and Brain @ Caen-Normandie, GIP Cyceron, 14000 Caen, France.

Elisa R Zanier (ER)

Department of Neuroscience, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, 20156 Milano, Italy. elisa.zanier@marionegri.it.

Classifications MeSH